JBM  Vol.7 No.1 , January 2019
Durational Therapeutic Dose of Fansidar: A Functional Index in Its Antidiabetic Properties
Abstract: Effects of fansidar in alloxan-induced diabetes were investigated in thirty (30) male and female albino rats for 28 days. The results showed a steady weekly decrease in blood glucose concentration in induced diabetic rats after fansidar treatment. In week 1, i.e. 7 days, there was significant difference in the blood glucose levels between the control and diabetic rats (P < 0.05) i.e. high glucose concentration, same in week II i.e. 14 days. However, in day 21 i.e. week III there was a significant reduction in the blood glucose concentration compared with control P < 0.05. The same results were obtained in week IV i.e. in 28 days treatment. The result has shown that fansidar has antidiabetic potentials on long term durational administration.
Cite this paper: Jimmy, E. (2019) Durational Therapeutic Dose of Fansidar: A Functional Index in Its Antidiabetic Properties. Journal of Biosciences and Medicines, 7, 23-28. doi: 10.4236/jbm.2019.71003.

[1]   Lazar, H.P., Hellgren, U.E. and Branden, J.A. (2000) Fansidar and Hepatic Granulomas. American Journal of Pharmacology, 102, 722.

[2]   Schweitzer, B.I., Dicker, A.P. and Bertino, J.R. (1990) Dihydrofolate Reductase as a Therapeutic Target. FASEB Journal, 4, 244-252.


[4]   Watkins, W.M. and Mosobo, M.A. (1993) Treatment of P. Falciparum Malaria with Pynmethamine-Sulphadoxine: Selective Pressure for Resistance. Journal of Tropical Medicine, 89, 75-78.

[5]   Hurwtz, E.S., Johnson, D. and Campbell, C.C. (1981) Resistance of Plasmodium, falciparum Malaria to Sulfadonine-Pyrimethamine (Fansidar) in a Refugee Camp in That Land. Lancet, 16, 1068-1070.

[6]   Edstin, M.D. (1978) Pharmacokinetics of Sulphadoxine & Pyrimethamine after Fansidar Administration. Chemotherapy, 33, 229-233.

[7]   Moshad, D., Chilongola, J., Ndeserua, R., Nwingira, F. and Genton, B. (2014) Effectiveness of Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine during Pregnancy in Placental Malarial, Maternalanaemia and Birth Weight in Areas with High and Low Malaria Transmission Intensity in Tanzania. Tropical Medicine & International Health, 19, 1048-1056.

[8]   Umar, E.A., Adebayo, J.M. and Cletus, C.E. (2012) The Role of Biotransformation in Elimination of Toxic Waste. Journal of Clinical Biochemistry, 51, 207-208.

[9]   Cunha, J.P. and Facoep, D.O. (2015) Side Effect of Fansidar Pyrimethamine/Sulphadoxine.

[10]   Alexis, N., John, O. and Anne, M.M. (2013) Impact of Folate Supplementation on Efficacy of Sulfadoxine/Pyrimethamine in Preventing Malaria in Pregnancy; the Potentials of 5-Methyl Tetrahydrofolate. Journal of Antimicrobial Therapy, 69, 323-330.

[11]   Huralikuppi, J.C. and Tatcho, M.A. (1998) Antidiabetic Effect of Nelumbo Nucifea Extract. Phytotherapy Research, 5, 217-223.

[12]   Ankur, R. and Shahjad, A. (2012) Alloxan Induced Diabetes: Mechanism and Effects. International Journal of Research in Pharmaceutical and Biomedical Sciences, 3, 819-823.

[13]   Osasenaga, M.I., Abiola, M.A. and Oluseyi, A.A. (2017) Alloxan Induced Diabetes a Common Model for Evaluating the Glycemic Control Potential of Therapeutic Compounds and Plant Extracts in Experimental Studies. Medicina, 63, 365-374.

[14]   Nelson, D.L. and Cox, M.M. (2000) Leninger; Principles of Biochemistry. 3rd Edition, Worth Publishers, Texas.


[16]   Dhaliwal, R. and Weinstock, R.S. (2014) Management of Diabetes in Older Adult.

[17]   Bellamy, L., Casas, J.-P., Hingorani, A.D. and Williams, D. (2009) Type 2 Diabetes Mellitus after Gestational Diabetes: A Systematic Review and Meta Analysis. The Lancet, 373, 1773-1779.

[18]   Pierre, D.M. (2016) The Insulin Receptor and Signal Transduction Network. Endotext (Internet).

[19]   WHO (2016) Global Report on Diabetes Mellitus. World Health Organization, Geneva.

[20]   Jimmy, E.O. and Udofia, A.J. (2014) Yoyo Bitters, a Potent Alternative Herbal Drug in the Treatment of Diabetes. International Journal of Innovative and Health Science, 2, 1-5.

[21]   Bertram, G. (2004) Basic and Clinical Pharmacology. Sanfrancisco, New York, Chicago.

[22]   Robert, G. (1979) Gastric Cytoprotective Property of Prostaglandins. Gastroenterology, 77, 762-769.

[23]   Lewis, S.M., Bain, B.J. and Bates, I. (2007) Dacie and Lewis Practical Haematology. 10th Edition, Churchill Livingstone, London.

[24]   Jimmy, E.O. and Okon, M.A. (2012) Periodic Validation of High Antidiabetic Potentials of Unripe Plantain in Comparison with Glibenclamide and Fansidar. American Journal of Pharmacology and Toxicology, 7, 15-18.

[25]   Nicholas, J.W. (2011) Determinants of Relapse of Periodicity in Plasmodium vivax Malaria. Malaria Journal, 10, 297.

[26]   Guyton, A.C. and Hall, J.E. (2006) Text Book of Medical Physiology. 11th Edition, Elsevier Saunders, Philadelphia, Pennsylvania.